A Randomised, Double-Blind, Placebo-Controlled, Exploratory Phase IIa Study To Assess The Safety And Efficacy Of Orally Administered DS102 In Patients With NAFLD
Phase of Trial: Phase II
Latest Information Update: 20 Oct 2017
At a glance
- Drugs DS 102 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Afimmune
- 20 Oct 2017 Status changed from not yet recruiting to recruiting, according to an Afimmune media release.
- 20 Oct 2017 According to an Afimmune media release, data read out is expected towards the end of 2018.
- 10 Nov 2015 New trial record